DK2640364T3 - Pharmaceutical composition with bicarbonate salt and its use as a drug in the treatment and / or prevention of urolithiasis and associated diseases - Google Patents

Pharmaceutical composition with bicarbonate salt and its use as a drug in the treatment and / or prevention of urolithiasis and associated diseases Download PDF

Info

Publication number: DK2640364T3
Authority: DK; Denmark
Prior art keywords: composition; weight; bicarbonate; hours; composition according
Prior art date: 2010-11-18

Application number

DK11796758.8T

Other languages

Danish (da)

English (en)

Inventor

Caroline Roussel-Maupetit

Luc-André Granier

Catherine Guittet

Original Assignee

Advicenne

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-18

Filing date

2011-11-18

Publication date

2017-05-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44168791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2640364(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-18 Application filed by Advicenne filed Critical Advicenne

2017-05-01 Application granted granted Critical

2017-05-01 Publication of DK2640364T3 publication Critical patent/DK2640364T3/en

Links

BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 title claims description 38
239000008194 pharmaceutical composition Substances 0.000 title claims description 20
238000011282 treatment Methods 0.000 title claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 11
201000010099 disease Diseases 0.000 title claims description 8
239000003814 drug Substances 0.000 title claims description 8
230000002265 prevention Effects 0.000 title claims description 5
206010007027 Calculus urinary Diseases 0.000 title claims description 4
208000008281 urolithiasis Diseases 0.000 title claims description 4
229940079593 drug Drugs 0.000 title 1
239000000203 mixture Substances 0.000 claims description 71
238000004090 dissolution Methods 0.000 claims description 46
239000011248 coating agent Substances 0.000 claims description 32
239000011736 potassium bicarbonate Substances 0.000 claims description 25
229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 25
235000015497 potassium bicarbonate Nutrition 0.000 claims description 25
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical group [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 25
230000002485 urinary effect Effects 0.000 claims description 22
238000000576 coating method Methods 0.000 claims description 21
239000011159 matrix material Substances 0.000 claims description 21
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 20
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 20
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
208000010444 Acidosis Diseases 0.000 claims description 17
238000013268 sustained release Methods 0.000 claims description 17
239000012730 sustained-release form Substances 0.000 claims description 17
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
238000000338 in vitro Methods 0.000 claims description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 11
239000008213 purified water Substances 0.000 claims description 11
239000001856 Ethyl cellulose Substances 0.000 claims description 10
208000026545 acidosis disease Diseases 0.000 claims description 10
235000019325 ethyl cellulose Nutrition 0.000 claims description 10
229920001249 ethyl cellulose Polymers 0.000 claims description 10
229920000642 polymer Polymers 0.000 claims description 10
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
230000007950 acidosis Effects 0.000 claims description 9
235000019359 magnesium stearate Nutrition 0.000 claims description 9
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 9
235000017557 sodium bicarbonate Nutrition 0.000 claims description 9
239000013543 active substance Substances 0.000 claims description 8
239000011230 binding agent Substances 0.000 claims description 8
235000010980 cellulose Nutrition 0.000 claims description 8
229920002678 cellulose Polymers 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
229960003943 hypromellose Drugs 0.000 claims description 8
238000001727 in vivo Methods 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
206010020590 Hypercalciuria Diseases 0.000 claims description 7
206010070871 Hypocitraturia Diseases 0.000 claims description 7
239000001913 cellulose Substances 0.000 claims description 7
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
239000008108 microcrystalline cellulose Substances 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 7
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 6
208000008852 Hyperoxaluria Diseases 0.000 claims description 6
229940049654 glyceryl behenate Drugs 0.000 claims description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
238000007922 dissolution test Methods 0.000 claims description 5
108010010803 Gelatin Proteins 0.000 claims description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
229920002125 Sokalan® Polymers 0.000 claims description 4
229920000615 alginic acid Polymers 0.000 claims description 4
235000010443 alginic acid Nutrition 0.000 claims description 4
239000004203 carnauba wax Substances 0.000 claims description 4
235000013869 carnauba wax Nutrition 0.000 claims description 4
229920000159 gelatin Polymers 0.000 claims description 4
239000008273 gelatin Substances 0.000 claims description 4
235000019322 gelatine Nutrition 0.000 claims description 4
235000011852 gelatine desserts Nutrition 0.000 claims description 4
229920000058 polyacrylate Polymers 0.000 claims description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
159000000000 sodium salts Chemical class 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
235000010981 methylcellulose Nutrition 0.000 claims description 3
235000019698 starch Nutrition 0.000 claims description 3
229920003002 synthetic resin Polymers 0.000 claims description 3
239000000057 synthetic resin Substances 0.000 claims description 3
229920002774 Maltodextrin Polymers 0.000 claims description 2
239000005913 Maltodextrin Substances 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
229920001800 Shellac Polymers 0.000 claims description 2
235000021355 Stearic acid Nutrition 0.000 claims description 2
150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
235000013871 bee wax Nutrition 0.000 claims description 2
239000012166 beeswax Substances 0.000 claims description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
235000013539 calcium stearate Nutrition 0.000 claims description 2
239000008116 calcium stearate Substances 0.000 claims description 2
239000004359 castor oil Substances 0.000 claims description 2
235000019438 castor oil Nutrition 0.000 claims description 2
229960001777 castor oil Drugs 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
229920001531 copovidone Polymers 0.000 claims description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 claims description 2
229910000022 magnesium bicarbonate Inorganic materials 0.000 claims description 2
235000014824 magnesium bicarbonate Nutrition 0.000 claims description 2
239000002370 magnesium bicarbonate Substances 0.000 claims description 2
229940035034 maltodextrin Drugs 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
239000012188 paraffin wax Substances 0.000 claims description 2
235000019809 paraffin wax Nutrition 0.000 claims description 2
235000019271 petrolatum Nutrition 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
229920000193 polymethacrylate Polymers 0.000 claims description 2
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
235000013874 shellac Nutrition 0.000 claims description 2
239000004208 shellac Substances 0.000 claims description 2
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
229940113147 shellac Drugs 0.000 claims description 2
239000000377 silicon dioxide Substances 0.000 claims description 2
239000008117 stearic acid Substances 0.000 claims description 2
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
239000000243 solution Substances 0.000 claims 4
239000006185 dispersion Substances 0.000 claims 2
239000012085 test solution Substances 0.000 claims 2
DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 claims 1
239000000872 buffer Substances 0.000 claims 1
239000008366 buffered solution Substances 0.000 claims 1
239000008199 coating composition Substances 0.000 claims 1
230000037406 food intake Effects 0.000 claims 1
239000000499 gel Substances 0.000 claims 1
239000000454 talc Substances 0.000 claims 1
229910052623 talc Inorganic materials 0.000 claims 1
239000000080 wetting agent Substances 0.000 claims 1
239000003826 tablet Substances 0.000 description 44
239000004480 active ingredient Substances 0.000 description 15
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 7
239000000126 substance Substances 0.000 description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
239000000463 material Substances 0.000 description 6
208000015924 Lithiasis Diseases 0.000 description 5
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000007906 compression Methods 0.000 description 5
230000006835 compression Effects 0.000 description 5
238000002156 mixing Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
-1 gums Polymers 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000002459 sustained effect Effects 0.000 description 4
229940116269 uric acid Drugs 0.000 description 4
229920006310 Asahi-Kasei Polymers 0.000 description 3
206010027417 Metabolic acidosis Diseases 0.000 description 3
208000009911 Urinary Calculi Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000002477 conductometry Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
229960003067 cystine Drugs 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
229940014259 gelatin Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000007939 sustained release tablet Substances 0.000 description 3
208000005223 Alkalosis Diseases 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
206010027423 Metabolic alkalosis Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
230000002340 alkalosis Effects 0.000 description 2
208000020832 chronic kidney disease Diseases 0.000 description 2
208000022831 chronic renal failure syndrome Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
159000000011 group IA salts Chemical class 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
231100000566 intoxication Toxicity 0.000 description 2
230000035987 intoxication Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
239000001993 wax Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
206010011778 Cystinuria Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
208000026019 Fanconi renotubular syndrome Diseases 0.000 description 1
201000006328 Fanconi syndrome Diseases 0.000 description 1
206010016818 Fluorosis Diseases 0.000 description 1
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
206010020601 Hyperchlorhydria Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
WHDLANJFNKEMKE-UHFFFAOYSA-N OC(=O)C([Ca])=O Chemical compound OC(=O)C([Ca])=O WHDLANJFNKEMKE-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000007950 delayed release tablet Substances 0.000 description 1
208000004042 dental fluorosis Diseases 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
208000016245 inborn errors of metabolism Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000008185 minitablet Substances 0.000 description 1
239000007912 modified release tablet Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000000025 natural resin Substances 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
201000005966 renal hypoplasia Diseases 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Botany (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK11796758.8T 2010-11-18 2011-11-18 Pharmaceutical composition with bicarbonate salt and its use as a drug in the treatment and / or prevention of urolithiasis and associated diseases DK2640364T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR1059472A FR2967577B1 (fr)	2010-11-18	2010-11-18	Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
PCT/FR2011/052695 WO2012066256A1 (fr)	2010-11-18	2011-11-18	Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament dans le traitement et/ou la prevention des lithiases urinaires et des maladies liees

Publications (1)

Publication Number	Publication Date
DK2640364T3 true DK2640364T3 (en)	2017-05-01

Family

ID=44168791

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11796758.8T DK2640364T3 (en)	2010-11-18	2011-11-18	Pharmaceutical composition with bicarbonate salt and its use as a drug in the treatment and / or prevention of urolithiasis and associated diseases

Country Status (9)

Country	Link
US (1)	US9662296B2 (fr)
EP (1)	EP2640364B9 (fr)
JP (1)	JP5879358B2 (fr)
DK (1)	DK2640364T3 (fr)
ES (1)	ES2622503T3 (fr)
FR (1)	FR2967577B1 (fr)
HU (1)	HUE032753T2 (fr)
PL (1)	PL2640364T3 (fr)
WO (1)	WO2012066256A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105434457A (zh) *	2014-09-23	2016-03-30	中山未标生物新技术有限公司	一种用于防治消化道癌性病变的肠溶口服制剂及其制备方法和其应用
JP6213591B2 (ja)	2016-02-25	2017-10-18	第一精工株式会社	コネクタ
US20210196747A1 (en) *	2018-05-25	2021-07-01	University Of The Ryukyus	Metabolism improving agent
CA3147731A1 (fr) *	2019-07-18	2021-01-21	C. Lowell Parsons	Alcalinisation de la paroi de la vessie urinaire avant traitement avec de l'heparine intravesicale et de la lidocaine alcalinisee pour ameliorer le soulagement des symptomes de la vessie douloureuse
CN111228239B (zh) *	2020-01-13	2022-04-22	厦门金达威生物科技有限公司	一种pH敏感型凝胶微胶囊及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4451454A (en)	1981-06-16	1984-05-29	Wong Dennis W	Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
GB2130087A (en) *	1982-09-22	1984-05-31	Dr Joachime Helbig	Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
IE80467B1 (en) *	1995-07-03	1998-07-29	Elan Corp Plc	Controlled release formulations for poorly soluble drugs
EP1970066A1 (fr) *	2007-03-12	2008-09-17	Medice Arzneimittel Pütter GmbH & Co. KG	Composition pharmaceutique destinée au traitement d'une hyperacidification du sang
RU2477123C2 (ru) *	2008-03-28	2013-03-10	Феррер Интернасионал, С.А.	Капсула и лекарственное средство для профилактики сердечно-сосудистых заболеваний
WO2009140341A2 (fr) *	2008-05-13	2009-11-19	Dr. Reddy's Laboratories Ltd.	Compositions d'atorvastatine

2010
- 2010-11-18 FR FR1059472A patent/FR2967577B1/fr active Active
2011
- 2011-11-18 WO PCT/FR2011/052695 patent/WO2012066256A1/fr not_active Ceased
- 2011-11-18 PL PL11796758T patent/PL2640364T3/pl unknown
- 2011-11-18 ES ES11796758.8T patent/ES2622503T3/es active Active
- 2011-11-18 JP JP2013539317A patent/JP5879358B2/ja active Active
- 2011-11-18 EP EP11796758.8A patent/EP2640364B9/fr active Active
- 2011-11-18 US US13/988,025 patent/US9662296B2/en active Active
- 2011-11-18 HU HUE11796758A patent/HUE032753T2/en unknown
- 2011-11-18 DK DK11796758.8T patent/DK2640364T3/en active

Also Published As

Publication number	Publication date
ES2622503T3 (es)	2017-07-06
US9662296B2 (en)	2017-05-30
PL2640364T3 (pl)	2017-09-29
HUE032753T2 (en)	2017-10-30
FR2967577B1 (fr)	2013-07-12
WO2012066256A1 (fr)	2012-05-24
EP2640364A1 (fr)	2013-09-25
EP2640364B9 (fr)	2017-08-30
JP2013542974A (ja)	2013-11-28
EP2640364B1 (fr)	2017-01-18
FR2967577A1 (fr)	2012-05-25
US20130230590A1 (en)	2013-09-05
JP5879358B2 (ja)	2016-03-08

Publication	Publication Date	Title
DK2640363T3 (en)	2015-12-14	Pharmaceutical composition with citrate and bicarbonate salts, use thereof for the treatment of cystinuria
US8067033B2 (en)	2011-11-29	Stable compositions of famotidine and ibuprofen
DK2640364T3 (en)	2017-05-01	Pharmaceutical composition with bicarbonate salt and its use as a drug in the treatment and / or prevention of urolithiasis and associated diseases
JP6386011B2 (ja)	2018-09-05	クレブス回路前駆体塩、特にクエン酸塩を含んでなる医薬組成物、及び医薬としてのこれらの使用
US20080020040A1 (en)	2008-01-24	Unit dose form for administration of ibuprofen
AU2006230557A1 (en)	2006-10-05	Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
US20150224056A1 (en)	2015-08-13	Pharmaceutical compositions of ibuprofen and famotidine
CN115804774B (zh)	2024-08-20	一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用
GB2624861A (en)	2024-06-05	Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof
US20130236538A1 (en)	2013-09-12	Pharmaceutical compositions of ibuprofen and famotidine
TR2022013357A2 (tr)	2024-03-21	Oral terapöti̇k formülasyonlar